JP Morgan Chase
PAND

JP Morgan Chase’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

JP Morgan Chase’s Portfolio PAND Stock Details PAND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-43,224
Closed -$2.6M – 6847
2021
Q1 		$2.6M Buy
43,224
+8,416
+24% +$305K ﹤0.01% 3502
2020
Q4 		$517K Buy
34,808
+32,021
+1,149% +$446K ﹤0.01% 4347
2020
Q3 		$33K Buy
+2,787
New +$47.6K ﹤0.01% 5063

JP Morgan Chase's PAND Position: Q2 2021 in Review

JP Morgan Chase sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 43,224 shares — an estimated $2.6M sold.

JP Morgan Chase first reported a position in PAND in Q3 2020 and held it in 3 quarters. The position peaked at $2.6M in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

  • JP Morgan Chase reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • JP Morgan Chase sold 43,224 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $2.6M.
  • JP Morgan Chase first reported a position in Pandion Therapeutics Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • JP Morgan Chase's Pandion Therapeutics Inc. Common Stock position peaked at $2.6M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on JP Morgan Chase's 13F filing for Q2 2021, filed 12 Aug 2021.